Clinical Trial: A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection

U.S., Jan. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07367529) titled 'A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection' on Jan. 16.

Brief Summary: To evaluate the efficacy and safety of TQB6411 for Injection in subjects with advanced lung cancer

Study Start Date: Jan., 2026

Study Type: INTERVENTIONAL

Condition: Advanced Lung Cancer

Intervention: DRUG: TQB6411 for Injection

TQB6411 for Injection is administered every 21 days as a treatment cycle.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Published by HT Digital Content Services with permission from Health Daily Digest....